

QR Pharma Announces the Appointment of New Chairman and New Board Member

Berwyn, Pa., January 4/5 ??, 2015/PRNewswire/ -- QR Pharma, Inc., a privately held biopharmaceutical company developing novel therapies for the treatment of Alzheimer's, Parkinson's and other neurodegenerative diseases, announced the election of Michael Hoffman to Chairman and of Dhesh Govender to Director of the Board. These appointments follow the recent opening of a Series A funding.

"We are thrilled to have Michael and Dhesh on our Board of Directors," said Maria L. Maccicchini, Chief Executive Officer of QR. "Michael brings a wealth of contacts in the financial as well as research community and his experience will be invaluable to QR for the company's strategy and funding and conduct of clinical studies with its lead compound Posiphen.

Michael Hoffman added, "....."

Michael, I abbreviated your bio, but it is still too long, can you shorten it and take out what you think is less important as it pertains to QR? Thanks

Mr. Hoffman is a Partner of Riverstone, where he is principally responsible for investments in power and renewable energy. Riverstone has committed approximately \$24.8 billion to 104 investments in North America, Latin America, Europe, Africa and Asia. Mr. Hoffman is co-head of Riverstone's Renewable Energy Funds I and II.

Before joining Riverstone in 2003, Mr. Hoffman was senior managing director and head of the mergers and acquisitions advisory business of The Blackstone Group for fifteen years, where he also served on the firm's principal group investment committee as well as its executive committee.

Mr. Hoffman serves on the Boards of Directors of Silver Ridge Power, AG Global, ThermaSource, Coastal Carolina, Enviva, Green Earth Fuels, Pattern Energy Group, Sapphire Power, Raven Power, and Topaz Power.

Mr. Hoffman is also the chairman of Onconova Therapeutics, an oncology company. Onconova is finishing both Phase II and Phase III trials for its lead compound which has activity in both solid and liquid tumors.

Mr. Hoffman is a co-author of the recently released book, *Green*. His non-profit board affiliations include those of North Shore-Long Island Jewish Health System and the Municipal Art Society. Mr. Hoffman is a Director of the Board of Rockefeller University and is a member of their Tech Transfer Committee. He has also funded their Tri-Institutional Therapeutic Discovery Institute which is a collaboration between Rockefeller, Cornell-Weill and Memorial Sloan Kettering.

Mr. Hoffman received his B.A. and M.A. from Northwestern University and his M.B.A. from the Harvard Business School. He is married to Jane Steiner Hoffman and has two children.

Dhesh Govender

**Dhesh: could you please send me a resume or bio? Thanks
Also can you add what you want me to say about you? Thanks**

About [Posiphen®](#): QR's lead compound, Posiphen, is a small orally active compound with high blood brain barrier permeability. Posiphen reduces the levels of toxic proteins in the brains of patients with neurodegenerative disorders back to the levels found in normal healthy volunteers. By normalizing brain levels of alpha synuclein, beta amyloid and tau, it provides an avenue to treat a number of neurodegenerative disorders and attack the disease at the onset. QR expects Posiphen to influence the disease early so as to prevent the onset or diminish the severity of cognitive decline. Since neurotoxic proteins cause inflammation in the brain, lowering their levels reduces inflammatory factors and lowers inflammation.

About QR Pharma: Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders. QR currently has three product development programs: Posiphen for early stage AD and PD, and BNC for advanced AD. For more information on QR Pharma, please visit the company's website, www.qrpharma.com.

Forward-Looking Statements:

Certain statements in this press release or made by management from time to time regarding QR Pharma that are not historical facts are "forward-looking statements," as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements.

Contact: Maria L. Maccecchini, CEO
Tel: 610 727 3710
maccecchini@qrpharma.com
www.qrpharma.com